Anti-CD3-anti-HER2/neu-activated T cells - TransTarget

Drug Profile

Anti-CD3-anti-HER2/neu-activated T cells - TransTarget

Alternative Names: Anti-CD3 activated T cells targeted with anti-CD3-anti-HER2 bispecific antibody; ATC targeted with HER2Bi; HER2Bi-armed ATC

Latest Information Update: 05 Aug 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator TransTarget
  • Developer Barbara Ann Karmanos Cancer Institute; National Cancer Institute (USA)
  • Class Bispecific antibodies; Cell therapies; Immunoconjugates; T lymphocyte cell therapies
  • Mechanism of Action Apoptosis stimulants; CD3 antigen inhibitors; ERBB 2 receptor antagonists; Immunostimulants; Macrophage stimulants; Natural killer cell stimulants; T lymphocyte replacements; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 18 Dec 2009 Phase-II clinical trials in Breast cancer in USA (IV)
  • 03 Jun 2008 Phase-I clinical trials in Breast cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top